Page last updated: 2024-10-27

gabapentin and MS (Multiple Sclerosis)

gabapentin has been researched along with MS (Multiple Sclerosis) in 29 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
"A prospective examiner-blind, cross-over study was conducted to compare the efficacy of memantine (40 or 60 mg/day) and gabapentin (1,200 mg/day) as therapy for acquired fixational pendular nystagmus (APN) in 11 patients with multiple sclerosis."9.14Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. ( Albrecht, H; Dieterich, M; Pöllmann, W; Starck, M; Straube, A, 2010)
"To investigate the effect of gabapentin on subject self-report and physician-administered spasticity scales in individuals with multiple sclerosis."9.09Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000)
"At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienced by patients with multiple sclerosis."9.08Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997)
"The authors retrospectively analysed Snellen visual acuity (VA), subjective visual function, and eye movement recordings of 23 patients with nystagmus (13 secondary to multiple sclerosis, three associated with other neurological diseases, two idiopathic infantile, and five with associated ocular diseases) treated with gabapentin or memantine."7.73The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006)
"We conducted an open-label trial of gabapentin (GBP) as therapy for paroxysmal symptoms (PS) in 21 MS patients, including trigeminal neuralgia (6 patients), painful tonic spasms (11), dysesthetic or paresthetic symptoms (3) and ocular ataxia (1)."7.70An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. ( Capello, E; Inglese, M; Lunardi, GL; Mancardi, GL; Messmer Uccelli, M; Solaro, C; Uccelli, A, 1998)
"This report describes the effectiveness of gabapentin, a recently approved anticonvulsant, in seven patients with MS experiencing trigeminal neuralgia refractory to treatment with conventional medical therapy."7.70Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. ( Khan, OA, 1998)
"Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy."6.68Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997)
"A prospective examiner-blind, cross-over study was conducted to compare the efficacy of memantine (40 or 60 mg/day) and gabapentin (1,200 mg/day) as therapy for acquired fixational pendular nystagmus (APN) in 11 patients with multiple sclerosis."5.14Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. ( Albrecht, H; Dieterich, M; Pöllmann, W; Starck, M; Straube, A, 2010)
"To investigate the effect of gabapentin on subject self-report and physician-administered spasticity scales in individuals with multiple sclerosis."5.09Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000)
"At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienced by patients with multiple sclerosis."5.08Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997)
"The authors retrospectively analysed Snellen visual acuity (VA), subjective visual function, and eye movement recordings of 23 patients with nystagmus (13 secondary to multiple sclerosis, three associated with other neurological diseases, two idiopathic infantile, and five with associated ocular diseases) treated with gabapentin or memantine."3.73The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006)
"A 40-year-old patient with acquired horizontal and vertical nystagmus and severe oscillopsia secondary to multiple sclerosis had combined treatment with gabapentin and a vertical Kestenbaum-type procedure."3.71Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis. ( Constantinescu, CS; Gottlob, I; Jain, S; Proudlock, F, 2002)
"We conducted an open-label trial of gabapentin (GBP) as therapy for paroxysmal symptoms (PS) in 21 MS patients, including trigeminal neuralgia (6 patients), painful tonic spasms (11), dysesthetic or paresthetic symptoms (3) and ocular ataxia (1)."3.70An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. ( Capello, E; Inglese, M; Lunardi, GL; Mancardi, GL; Messmer Uccelli, M; Solaro, C; Uccelli, A, 1998)
"This report describes the effectiveness of gabapentin, a recently approved anticonvulsant, in seven patients with MS experiencing trigeminal neuralgia refractory to treatment with conventional medical therapy."3.70Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. ( Khan, OA, 1998)
"Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy."2.68Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997)
"Mycophenolic acid was detected in all cats."2.61 ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of available drugs."2.53Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016)
"The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol."2.48[Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012)
"Among the more common symptoms is spasticity."2.41Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001)
"Treatment of spasticity includes oral and intrathecal anti-spastic drugs, muscle injections with relaxant agents, physical therapy, electrical and magnetic stimulation and peripheral nerve stimulation, alone or in various combinations."1.56Italian consensus on treatment of spasticity in multiple sclerosis. ( Centonze, D; Comi, G; Leocani, L; Otero-Romero, S; Solari, A, 2020)
"Although mouse models of experimental autoimmune encephalomyelitis (EAE) have provided insight on the pathobiology of MS-induced neuropathic pain, concurrent severe motor impairments confound quantitative assessment of pain behaviors over the disease course."1.40Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. ( Khan, N; Smith, MT; Woodruff, TM, 2014)
"Acquired pendular nystagmus (APN) occurs with multiple sclerosis (MS) and oculopalatal tremor (OPT); distinct features of the nystagmus have led to the development of separate models for their pathogenesis."1.37Pharmacological tests of hypotheses for acquired pendular nystagmus. ( Leigh, RJ; Optican, LM; Shaikh, AG; Thurtell, MJ, 2011)
"Carbamazepine (CBZ) was prescribed in 36 patients, with adverse effects reported in 20 cases, of which 12 mimicked a relapse."1.33Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. ( Battaglia, MA; Brichetto, G; Mancardi, GL; Messmer Uccelli, M; Solaro, C, 2005)
"Acquired Pendular Nystagmus (APN) may cause distressing visual symptoms in patients who are already suffering a severe general disease."1.31Improvement of acquired pendular nystagmus by gabapentin: case report. ( Fabre, K; Smet-Dieleman, H; Zeyen, T, 2001)

Research

Studies (29)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's7 (24.14)18.2507
2000's12 (41.38)29.6817
2010's9 (31.03)24.3611
2020's1 (3.45)2.80

Authors

AuthorsStudies
Bobenko, AI1
Heller, S1
Schmitt, N1
Cherdtrakulkiat, R1
Lawung, R1
Nabu, S1
Tantimavanich, S1
Sinthupoom, N1
Prachayasittikul, S1
Prachayasittikul, V1
Zhang, B1
Wu, C1
Zhang, Z2
Yan, K1
Li, C2
Li, Y4
Li, L3
Zheng, C1
Xiao, Y1
He, D1
Zhao, F1
Su, JF1
Lun, SM1
Hou, YJ1
Duan, LJ1
Wang, NC1
Shen, FF1
Zhang, YW1
Gao, ZW1
Li, J5
Du, XJ1
Zhou, FY1
Yin, Z1
Zhu, J2
Yan, D1
Lou, H1
Yu, H1
Feng, C1
Wang, Z1
Wang, Y4
Hu, X1
Li, Z2
Shen, Y1
Hu, D1
Chen, H1
Wu, X1
Duan, Y1
Zhi, D1
Zou, M2
Zhao, Z1
Zhang, X2
Yang, X2
Zhang, J2
Wang, H1
Popović, KJ1
Popović, DJ1
Miljković, D1
Lalošević, D1
Čapo, I1
Popović, JK1
Liu, M1
Song, H2
Xing, Z1
Lu, G1
Chen, D1
Valentini, AM1
Di Pinto, F1
Coletta, S1
Guerra, V1
Armentano, R1
Caruso, ML1
Gong, J1
Wang, N1
Bian, L1
Wang, M1
Ye, M1
Wen, N1
Fu, M1
Fan, W1
Meng, Y1
Dong, G1
Lin, XH1
Liu, HH1
Gao, DM1
Cui, JF1
Ren, ZG1
Chen, RX1
Önal, B1
Özen, D1
Demir, B1
Akkan, AG1
Özyazgan, S1
Payette, G1
Geoffroy, V1
Martineau, C1
Villemur, R1
Jameel, T1
Baig, M1
Gazzaz, ZJ1
Tashkandi, JM1
Al Alhareth, NS1
Khan, SA1
Butt, NS1
Wang, J2
Geng, Y1
Zhang, Y3
Wang, X2
Liu, J2
Basit, A1
Miao, T1
Liu, W1
Jiang, W1
Yu, ZY1
Wu, L2
Qu, B1
Sun, JX1
Cai, AL1
Xie, LM1
Groeneveld, J1
Ho, SL1
Mackensen, A1
Mohtadi, M1
Laepple, T1
Genovesi, S1
Nava, E1
Bartolucci, C1
Severi, S1
Vincenti, A1
Contaldo, G1
Bigatti, G1
Ciurlino, D1
Bertoli, SV1
Slovak, JE1
Hwang, JK1
Rivera, SM1
Villarino, NF1
Li, S1
Cao, G1
Ling, M1
Ji, J1
Zhao, D1
Sha, Y1
Gao, X1
Liang, C2
Guo, Q1
Zhou, C1
Ma, Z1
Xu, J1
Wang, C1
Zhao, W1
Xia, X1
Jiang, Y1
Peng, J1
Jia, Z1
Li, F1
Chen, X2
Mo, J1
Zhang, S2
Li, X1
Huang, T1
Zhu, Q1
Wang, S1
Ge, RS1
Fortunato, G1
Lin, J2
Agarwal, PK1
Kohen, A1
Singh, P1
Cheatum, CM1
Zhu, D1
Hayman, A1
Kebede, B1
Stewart, I1
Chen, G1
Frew, R1
Guo, X1
Gong, Q1
Borowiec, J1
Han, S1
Zhang, M1
Willis, M1
Kreouzis, T1
Yu, K1
Chirvony, VS1
Sekerbayev, KS1
Pérez-Del-Rey, D1
Martínez-Pastor, JP1
Palazon, F1
Boix, PP1
Taurbayev, TI1
Sessolo, M1
Bolink, HJ1
Lu, M1
Lan, Y1
Xiao, J1
Song, M1
Chen, C1
Huang, Q1
Cao, Y1
Ho, CT1
Qi, B1
Wang, Q1
Zhang, W1
Fang, L1
Xie, CL1
Chen, R1
Yang, S1
Xia, JM1
Zhang, GY1
Chen, CH1
Yang, XW1
Domenech-Ximenos, B1
Garza, MS1
Prat-González, S1
Sepúlveda-Martínez, Á1
Crispi, F1
Perea, RJ1
Garcia-Alvarez, A1
Sitges, M1
Kalumpha, M1
Guyo, U1
Zinyama, NP1
Vakira, FM1
Nyamunda, BC1
Varga, M1
Drácz, L1
Kolbenheyer, E1
Varga, F1
Patai, ÁV1
Solymosi, N1
Patai, Á1
Kiss, J1
Gaál, V1
Nyul, Z1
Mosdósi, B1
Valdez, M1
Moosavi, L1
Heidari, A1
Novakovic-Agopian, T1
Kornblith, E1
Abrams, G1
McQuaid, JR1
Posecion, L1
Burciaga, J1
D'Esposito, M1
Chen, AJW1
Samy El Gendy, NM1
Wesolowska, P1
Georg, D1
Lechner, W1
Kazantsev, P1
Bokulic, T1
Tedgren, AC1
Adolfsson, E1
Campos, AM1
Alves, VGL1
Suming, L1
Hao, W1
Ekendahl, D1
Koniarova, I1
Bulski, W1
Chelminski, K1
Samper, JLA1
Vinatha, SP1
Rakshit, S1
Siri, S1
Tomsejm, M1
Tenhunen, M1
Povall, J1
Kry, SF1
Followill, DS1
Thwaites, DI1
Izewska, J1
Kang, JH1
Yoon, Y1
Song, J1
Van de Winckel, A1
Gauthier, L1
Chao, CT1
Lee, YH1
Li, CM1
Han, DS1
Huang, JW1
Huang, KC1
Ni, L1
Güttinger, R1
Triana, CA1
Spingler, B1
Baldridge, KK1
Patzke, GR1
Shen, X1
Wang, B1
Xie, S1
Deng, W1
Wu, D1
Zhang, Q1
Voskamp, BJ1
Peelen, MJCS1
Ravelli, ACJ1
van der Lee, R1
Mol, BWJ1
Pajkrt, E1
Ganzevoort, W1
Kazemier, BM1
Tibrewala, R1
Bahroos, E1
Mehrabian, H1
Foreman, SC1
Link, TM1
Pedoia, V1
Majumdar, S1
Jablonski, CL1
Leonard, C1
Salo, P1
Krawetz, RJ1
Yoon, N1
Hong, SN1
Cho, JG1
Jeong, HK1
Lee, KH1
Park, HW1
Barman, S1
Konai, MM1
Samaddar, S1
Haldar, J1
Mohamed, HSH1
Li, CF1
Hu, ZY1
Deng, Z1
Chen, LH1
Su, BL1
Chu, K1
Liu, YP1
Li, YB1
Zhang, H1
Xu, C1
Zou, Z1
Wu, Z1
Xia, Y1
Zhao, P1
Wang, HT1
de Biase, S1
Pellitteri, G1
Gigli, GL1
Valente, M1
Comi, G2
Solari, A1
Leocani, L1
Centonze, D1
Otero-Romero, S2
Redon, S1
Graillon, N1
Régis, J1
Donnet, A1
Khan, N1
Woodruff, TM1
Smith, MT1
Trojano, M1
Sastre-Garriga, J1
Hartung, HP1
Soelberg Sørensen, P1
Thompson, AJ1
Vermersch, P1
Gold, R1
Montalban, X1
Starck, M1
Albrecht, H1
Pöllmann, W1
Dieterich, M1
Straube, A1
Bittner, S1
Höhn, K1
Göbel, K1
Kleinschnitz, C1
Wiendl, H1
Meuth, SG1
Shaikh, AG1
Thurtell, MJ1
Optican, LM1
Leigh, RJ2
Heinzlef, O1
Monteil-Roch, I1
Jain, S1
Proudlock, F1
Constantinescu, CS1
Gottlob, I3
Fabre, K1
Smet-Dieleman, H1
Zeyen, T1
Yetimalar, Y1
Gürgör, N1
Başoğlu, M1
Hsu, C1
Sliwa, JA1
Sarrigiannis, P1
Tsakanicas, C1
Anagnostouli, M1
Karandreas, N1
Solaro, C5
Brichetto, G1
Battaglia, MA1
Messmer Uccelli, M2
Mancardi, GL5
Shery, T1
Proudlock, FA1
Sarvananthan, N2
McLean, RJ1
Choudhuri, I1
Mueller, ME1
Gruenthal, M1
Olson, WL1
Olson, WH1
Samkoff, LM1
Daras, M1
Tuchman, AJ1
Koppel, BS1
Houtchens, MK1
Richert, JR1
Sami, A1
Rose, JW1
Lunardi, GL1
Capello, E1
Inglese, M1
Uccelli, A2
Khan, OA1
Uccelli, MM2
Cutter, NC1
Scott, DD1
Johnson, JC1
Whiteneck, G1
Guglieri, P1
Bandini, F1
Castello, E1
Mazzella, L1
Stahl, JS1
Rottach, KG1
Averbuch-Heller, L1
von Maydell, RD1
Collins, SD1
Schapiro, RT1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595]36 participants (Anticipated)Interventional2023-05-18Recruiting
Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187]8 participants (Actual)Interventional2009-11-30Terminated (stopped due to PI left institution)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

5 reviews available for gabapentin and MS (Multiple Sclerosis)

ArticleYear
    Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

    Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P

2019
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:11

    Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze

2016
[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications].
    Der Nervenarzt, 2011, Volume: 82, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Antineoplastic Agents; Carbamazepine; Cohor

2011
[Pharmacological treatment of spasticity in multiple sclerosis].
    Revue neurologique, 2012, Volume: 168 Suppl 3

    Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant

2012
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
    Current neurology and neuroscience reports, 2001, Volume: 1, Issue:3

    Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin

2001

Trials

7 trials available for gabapentin and MS (Multiple Sclerosis)

ArticleYear
Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin.
    Journal of neurology, 2010, Volume: 257, Issue:3

    Topics: Adult; Amines; Brain Stem; Clinical Protocols; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dose

2010
Clinical efficacy of gabapentin for paroxysmal symptoms in multiple sclerosis.
    Acta neurologica Scandinavica, 2004, Volume: 109, Issue:6

    Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami

2004
Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis.
    Archives of physical medicine and rehabilitation, 1997, Volume: 78, Issue:5

    Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarboxylic Acid

1997
Open label gabapentin treatment for pain in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 1997, Volume: 3, Issue:4

    Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gab

1997
Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial.
    Archives of physical medicine and rehabilitation, 2000, Volume: 81, Issue:2

    Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Cross-Over Studies; C

2000
Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2000, Volume: 6, Issue:3

    Topics: Acetates; Amines; Anticonvulsants; Circadian Rhythm; Cyclohexanecarboxylic Acids; Gabapentin; gamma-

2000
Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis?
    Journal of neurology, neurosurgery, and psychiatry, 2001, Volume: 71, Issue:1

    Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Electrooculography; Female; Gabapentin; gamma-

2001

Other Studies

17 other studies available for gabapentin and MS (Multiple Sclerosis)

ArticleYear
Italian consensus on treatment of spasticity in multiple sclerosis.
    European journal of neurology, 2020, Volume: 27, Issue:3

    Topics: Baclofen; Botulinum Toxins; Clonidine; Consensus; Disease Management; Gabapentin; Humans; Injections

2020
First Bite Syndrome After Trigeminal Radiosurgery: Case Report and Pathophysiology.
    Headache, 2018, Volume: 58, Issue:10

    Topics: Adult; Carbamazepine; Cheek; Combined Modality Therapy; Drug Therapy, Combination; Facial Muscles; F

2018
Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods.
    Pharmacology, biochemistry, and behavior, 2014, Volume: 126

    Topics: Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cyclohexanecarboxyli

2014
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
    European neurology, 2016, Volume: 75 Suppl 1

    Topics: Adult; Amines; Baclofen; Calcium Channel Blockers; Cannabidiol; Cohort Studies; Cyclohexanecarboxyli

2016
Pharmacological tests of hypotheses for acquired pendular nystagmus.
    Annals of the New York Academy of Sciences, 2011, Volume: 1233

    Topics: Amines; Baclofen; Cerebellar Cortex; Cyclohexanecarboxylic Acids; Eye Movements; Gabapentin; gamma-A

2011
Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis.
    American journal of ophthalmology, 2002, Volume: 134, Issue:5

    Topics: Acetates; Adult; Amines; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Diplopia; Excitator

2002
Improvement of acquired pendular nystagmus by gabapentin: case report.
    Bulletin de la Societe belge d'ophtalmologie, 2001, Issue:282

    Topics: Acetates; Administration, Oral; Amines; Baclofen; Cyclohexanecarboxylic Acids; Female; Gabapentin; g

2001
Phantom breast pain as a source of functional loss.
    American journal of physical medicine & rehabilitation, 2004, Volume: 83, Issue:8

    Topics: Acetates; Activities of Daily Living; Amines; Anti-Anxiety Agents; Breast Neoplasms; Carcinoma in Si

2004
Spastic paretic hemifacial contracture (SPHC) in a patient with multiple sclerosis. A clinical, EMG and neuroimaging study.
    Neurophysiologie clinique = Clinical neurophysiology, 2004, Volume: 34, Issue:3-4

    Topics: Adult; Amines; Baclofen; Blinking; Brain; Clonazepam; Cyclohexanecarboxylic Acids; Electromyography;

2004
Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2005, Volume: 25, Issue:6

    Topics: Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Follow-Up Studies;

2005
The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study.
    The British journal of ophthalmology, 2006, Volume: 90, Issue:7

    Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gab

2006
Survey of management of acquired nystagmus in the United Kingdom.
    Eye (London, England), 2007, Volume: 21, Issue:9

    Topics: Amines; Baclofen; Cyclohexanecarboxylic Acids; Drug Utilization; Excitatory Amino Acid Antagonists;

2007
Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin.
    Neurology, 1997, Volume: 49, Issue:1

    Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut

1997
An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients.
    Neurology, 1998, Volume: 51, Issue:2

    Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami

1998
Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients.
    Neurology, 1998, Volume: 51, Issue:2

    Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut

1998
A patient with multiple sclerosis and Down's syndrome with a rare paroxysmal symptom at onset.
    European journal of neurology, 1999, Volume: 6, Issue:4

    Topics: Acetates; Amines; Brain; Cyclohexanecarboxylic Acids; Down Syndrome; Excitatory Amino Acid Antagonis

1999
A pilot study of gabapentin as treatment for acquired nystagmus.
    Neuro-ophthalmology (Aeolus Press), 1996, Volume: 16, Issue:2

    Topics: Acetates; Adult; Amines; Anticonvulsants; Brain Stem; Cerebrovascular Disorders; Cyclohexanecarboxyl

1996